OBJECTIVE: To determine the safety of intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery given at a dose of 500 mg/0.1 mL.
METHODS: Medical records of uncomplicated phacoemulsification performed between January 2009 and December 2010 were reviewed. Each eye received 0.1 mL intracameral moxifloxacin (0.5% ophthalmic solution containing 500 mg of moxifloxacin) prophylactically. Outcome measures included anterior chamber cells and flare (Hogan System), corneal thickness, endothelial cell density, visual acuity, and intraocular pressure.
RESULTS: 353 eyes of 244 patients, mean age of 67.51 ± 9.22 years, were included into the study. All patients completed follow-up to 3 weeks, with 79 patients (103 eyes) followed up to 3 months. All eyes had 20/40 or better vision at 3 weeks and 3 months postoperatively. Trace to +2 anterior chamber cells and flares were observed in 96% of eyes on day 1 postsurgery. All had quiet anterior chambers at subsequent follow-up examinations. Intraocular pressures recorded postoperatively were not significantly different. Mean endothelial cell count (ECC) postoperatively were 2473.25 cells/mm2 at 3 weeks and 2468.42 cells/mm2 at 3 months and were not significantly different from baseline (2586.57 cells/mm2) (p = 0.07 and 0.12 respectively). The mean central corneal thickness postoperatively at 3 weeks (551.92 µm) and at 3 months (542.67 µm ) were not different from baseline (546.48 µm) (p = 0.47). Those with diabetes mellitus showed similar results.
CONCLUSION: Intracameral moxifloxacin 0.5% appears to be safe for prophylactic use in cataract surgery. At a dose of 500 mg/0.1 mL, there was minimal anterior chamber reaction, and the corneal thickness and endothelial cell density were not significantly different from preoperative.

Human ; Male ; Female ; Aged ; Middle Aged ; Phacoemulsification ; Moxifloxacin ; Intraocular Pressure ; Aza Compounds ; Anterior Chamber ; Cataract Extraction ; Cataract ; Ophthalmic Solutions ; Diabetes Mellitus ; Endothelial Cells

Objective: To present a case of peripheral ulcerative keratitis (PUK) in a patient with Sweet syndrome (acute febrile neutrophilic dermatosis) and discuss its etiopathogenesis, clinical presentation, course, and management. Method: This is a case report. Results: A 31-year-old male, diagnosed with Sweet syndrome, was referred for redness, photophobia, and severe, deep, boring pain in the right eye. Visual acuity was 20/20 bilaterally. Inferior sectoral conjunctival and scleral hyperemia were present in the right eye. Initial treatment included topical and oral nonsteroidal antiinflammatory drugs (NSAIDs), a topical immunosuppressive agent, and an antibiotic. One month after treatment, the pain decreased but patient developed peripheral corneal thinning that gradually spread circumferentially and centrally in the right eye. Vision decreased to 20/400. A similar inferior sectoral injection was noted in the left eye. Oral prednisone was started, followed by oral immunosuppressive agent. Resolution of the PUK was noted after 1 month of immunosuppressive treatment with improvement of the vision. Conclusion PUK is a potentially blinding disorder that can be seen in Sweet syndrome. With proper knowledge of the underlying disease, close monitoring and management, PUK can be treated and cured.
Sweet Syndrome ; Conjunctivitis